A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
Completed · Phase 3
Conditions studied: Cytomegalovirus Infections
In brief
The purpose of this study is to evaluate the benefits and safety of the antiviral drug ganciclovir (DHPG) given intravenously to treat newborn infants who are born infected with cytomegalovirus (CMV). CMV is a herpes virus that can infect most organs of the body, resulting in death in 10-30% of babies with symptoms of CMV. It can cause severe brain damage in a large percentage of surviving babies. Children in this study have a CMV infection of the central nervous system (CNS).
Key facts
- Study ID
- NCT00001100
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 130
- Expected to finish
- 2005-11-01
- Last updated by the study team
- 2010-08-27
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Infants may be eligible for this study if they:
- Were full term infants (at least 32 weeks gestation).
- Are 1 month of age or younger (preferably less than 2 weeks).
- Weighed at least 1,200 grams (2.5 lbs) at birth.
- Have confirmed cytomegalovirus.
- Have evidence of CMV infection of the CNS with or without evidence of other organ involvement.
You may not qualify if…
- Infants will not be eligible for this study if they:
- Have concurrent bacterial infection.
- Have HIV infection.
- Have mild symptoms or no symptoms of CMV infection at birth.
- Have an abnormal brain development (hydranencephaly) or any devastating brain involvement.
Where it is running
- NIAID/DMID/CASG Central Unit — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.